



TOPAZ Interim Analysis: SRK-015 Demonstrates Clinical Proof-of-Concept in Spinal Muscular Atrophy

October 27, 2020



Disclaimers

Various statements in this presentation concerning the future expectations, plans and prospects of Scholar Rock, Inc. (“Scholar Rock”), including without limitation, Scholar Rock’s expectations regarding its strategy, its product candidate selection and development timing, including timing for the initiation of and reporting results from its clinical trials for its product candidates, its disease indication selection and timing for such selection, the ability of SRK-015 to affect the treatment of patients suffering from Spinal Muscular Atrophy (SMA) either as a monotherapy or in conjunction with the current standard of care, and the ability of SRK-181 to affect the treatment of cancer patients in a manner consistent with preclinical data constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “target,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify such forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Scholar Rock’s ability to provide the financial support and resources necessary to identify and develop multiple product candidates on the expected timeline, competition from others developing products for similar uses, the preliminary nature of interim clinical data, Scholar Rock’s ability to obtain, maintain and protect its intellectual property, Scholar Rock’s dependence on third parties for development and manufacture of product candidates including to supply any clinical trials, and Scholar Rock’s ability to manage expenses and to obtain additional funding when needed to support its business activities and establish and maintain strategic business alliances and new business initiatives as well as those risks more fully discussed in the section entitled “Risk Factors” in the Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, which is on file with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties, and other important factors in Scholar Rock’s subsequent filings with the Securities and Exchange Commission. Any forward-looking statements represent Scholar Rock’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Scholar Rock explicitly disclaims any obligation to update any forward-looking statements unless required by law.

Agenda



Opening Remarks

Tony Kingsley, President & CEO

Trial Design and Baseline Characteristics

Yung Chyung M.D., Chief Medical Officer

6-month Interim Efficacy and Safety Results

Yung Chyung M.D., Chief Medical Officer

Summary and Next Steps


Tony Kingsley, President & CEO

Questions and Answers

Tony Kingsley, President & CEO
Yung Chyung M.D., Chief Medical Officer
Ted Myles, Chief Financial Officer

SRK-015 Has Potential to Pioneer a New Treatment Era to Improve Motor Function in Patients with SMA

SMN Upregulator Therapies + Muscle-Directed Therapy (SRK-015)
Could Potentially Enhance Outcomes for Patients*



SRK-015**

SMN = survival motor neuron.

**Also referred to as SMN correctors.*

***SRK-015 is an investigational therapy under development.*

SRK-015: Highly Selective Inhibitor of the Activation of Pro and Latent Myostatin



- Fully human monoclonal antibody (mAb)
- Half-life of ~23-33 days
- Avoids related growth factors (e.g. GDF11, BMP9, Activin A)
-
- Rare Pediatric Disease Designation for SMA granted by FDA
- Orphan Drug Designation for SMA granted by the FDA
- Orphan Medicinal Product Designation for SMA granted by the European Commission


Highlights of strong patent portfolio protecting SRK-015:

- **US Patent 10,751,413 (expiry in 2037):** Covers composition of matter and methods of use for SRK-015
- **US Patent 9,758,576 (expiry in 2034):** Covers mAbs that inhibit the activation of myostatin precursor
- **US 10,287,345 (expiry in 2037):** Treatment methods for various myostatin-related conditions

Bringing a Revolutionary Approach to Highly Sought-After Growth Factors Implicated in Devastating Diseases

Scholar Rock's Target

Growth Factor Precursor (Latent Form)



Scholar Rock's R&D Platform

Transform Medical Practice

- Pursue important targets with well-validated biology but are difficult to drug
- Apply revolutionary approach to tough targets
 - Leverage deep insights into structure and function
 - Engineer antibodies for exquisite selectivity

First demonstration of the therapeutic potential of inhibiting the latent forms of growth factors

TOPAZ Interim Analysis Results Demonstrate Proof-of-Concept

Multiple lines of evidence supporting the potential clinical effect of SRK-015

	Ambulatory Patients (Revised Hammersmith Scale)			Non-Ambulatory Patients (Hammersmith Functional Motor Scale Expanded)		
	Cohort 1			Cohort 2*	Cohort 3*	
	20 mg/kg pooled (n=23)	20 mg/kg monotherapy (n=11)	20 mg/kg +nusinersen (n=12)	20 mg/kg +nusinersen (n=14)	2 mg/kg +nusinersen (n=9)	20 mg/kg +nusinersen (n=9)
Mean change from baseline (95% CI)	0.5 (-1.1, 2.2)	0.7 (-2.5, 4.0)	0.3 (-1.4, 2.0)	1.4 (0.1, 2.7)	2.4 (-0.9, 5.8)	5.6 (2.5, 8.7)
# (%) patients achieving ≥ 1 -pt increase	12/23 (52%)	7/11 (64%)	5/12 (42%)	10/14 (71%)	6/9 (67%)	9/9 (100%)
# (%) patients achieving ≥ 3 -pt increase	6/23 (26%)	4/11 (36%)	2/12 (17%)	3/14 (21%)	4/9 (44%)	6/9 (67%)

- ✓ **Mean improvements from baseline in HFMSE/RHS observed in each of the 3 cohorts**
 - 67% of total patients achieved ≥ 1 -point improvement in Hammersmith scores
- ✓ **Substantial proportion of patients in each cohort attained ≥ 3 -point improvement in HFMSE/RHS**
 - High bar and uncommon to observe in any given patient
 - 35% of total patients achieved ≥ 3 -point improvement in Hammersmith scores
- ✓ **Dose response demonstrated in Cohort 3 (*randomized, double-blind, parallel arm design*)**
 - Greater improvements in HFMSE scores for high-dose arm across evaluated timepoints
 - Supportive PK/PD results; high dose led to higher drug exposure and target engagement

*3 patients (1 in Cohort 2 and 2 in Cohort 3) each missed 3 doses of SRK-015 and the 6-month interim analysis timepoint due to COVID-19-related site access restrictions; the six-month timepoint from these patients was not included in the interim analysis.
Data on file. Scholar Rock, Inc. Cambridge, MA

Phase 2 Trial Design and Baseline Characteristics

Yung Chyung, M.D.
Chief Medical Officer



Next Era of SMA Treatment: Muscle-Directed Therapy

Overall Prevalence of 30,000-35,000 in U.S. and Europe

Type 1:

- Infant-onset
- Usually fatal without treatment


Type 2 and non-ambulatory Type 3:

- Later-onset but still early childhood
- Severe deficits in motor function
- SMN upregulators appear to primarily stabilize disease course

Ambulatory Type 3:

- Typically childhood-onset
- Wide range of motor function deficits; limited mobility and substantial morbidity
- SMN upregulators appear to primarily stabilize disease course

Relative Prevalence Among Patients Living With SMA



TOPAZ trial focuses on Type 2 and Type 3 SMA

Unmet need would be served by a therapy that:

- Improves motor function
- Safety profile that enables chronic dosing, including in the pediatric population
- Low drug administration burden
- Applicable across SMA types

SRK-015 Phase 2 Trial Design



	Ambulatory Patients (Revised Hammersmith Scale)	Non-Ambulatory Patients (Hammersmith Functional Motor Scale Expanded)	
	Cohort 1	Cohort 2	Cohort 3
Design	<ul style="list-style-type: none"> N= 23; ages 5-21 Open-label, single-arm 20 mg/kg SRK-015 IV Q4W 12-month treatment period 	<ul style="list-style-type: none"> N= 15; ages 5-21 Open-label, single-arm 20 mg/kg SRK-015 IV Q4W 12-month treatment period 	<ul style="list-style-type: none"> N= 20; ages ≥ 2 Double-blind, randomized (1:1) to 2 mg/kg or 20 mg/kg SRK-015 IV Q4W 12-month treatment period
Patients	<ul style="list-style-type: none"> Ambulatory Type 3 SMA Two subgroups: <ol style="list-style-type: none"> Receiving background nusinersen SRK-015 monotherapy 	<ul style="list-style-type: none"> Type 2 or non-ambulatory Type 3 SMA Receiving background nusinersen 	<ul style="list-style-type: none"> Type 2 SMA Receiving background nusinersen (initiated before age 5)
Primary Objectives	<ul style="list-style-type: none"> Safety Mean change from baseline in RHS 	<ul style="list-style-type: none"> Safety Mean change from baseline in HFMSE 	<ul style="list-style-type: none"> Safety Mean change from baseline in HFMSE

Evaluate potential of SRK-015 in improving motor function

Baseline Characteristics

	Ambulatory Patients			Non-Ambulatory Patients		
	Cohort 1			Cohort 2	Cohort 3	
	20 mg/kg pooled	20 mg/kg monotherapy	20 mg/kg +nusinersen	20 mg/kg +nusinersen	2 mg/kg +nusinersen	20 mg/kg +nusinersen
N	23	11	12	15	10	10
Mean age (min, max)	12.6 (7, 21)	12.1 (7, 19)	13.1 (7, 21)	11.7 (8, 19)	4.1 (2, 6)	3.8 (2, 6)
Female (%)	65%	73%	58%	53%	30%	50%
SMN2 Gene Copy* (#, %)						
2	1 (4%)	1 (9%)	0 (0%)		1 (10%)	1 (10%)
3	13 (57%)	4 (36%)	9 (75%)	11 (73%)	8 (80%)	8 (80%)
4	5 (22%)	4 (36%)	1 (8%)	2 (13%)	1 (10%)	0 (0%)
Mean # of nusinersen maintenance doses	N/A	N/A	5.6	5.1	5.5	5.4
Discontinuation(s)	1**	0	1**	0	0	0
Mean RHS score (min, max)	49.6 (26, 63)	47.6 (26, 63)	51.3 (43, 62)			
Mean HFMSE score (min, max)				22.7 (13, 39)	26.1 (12, 44)	23.5 (14, 42)

*data not available for all patients

**patient who discontinued study for reasons unrelated to study drug

HFMSE=Hammersmith Functional Motor Scale Expanded; RHS=Revised Hammersmith Scale
Data on file. Scholar Rock, Inc. Cambridge, MA

Key Strengths of TOPAZ Trial Design and Conduct

- **Large and diverse group of study sites for a rare disease trial**
 - Patients enrolled across 16 study sites in the U.S. and Europe
 - Patient enrollment was not skewed to any one site for any cohort or across the study
- **Primary efficacy endpoints are well-validated outcome measures**
 - Hammersmith Functional Motor Scale Expanded (HF MSE) was specifically designed for SMA and served as primary efficacy endpoint in Phase 3 CHERISH trial of nusinersen
 - Revised Hammersmith Scale (RHS) is very similar to the HF MSE, with some modification to reduce ceiling effects in assessing patients who are ambulatory
- **Efficacy assessments are being conducted in a rigorous fashion:**
 - Standardized conduct of Hammersmith scale assessments; extensive training of all trial sites
 - Assessors of the Hammersmith scale measures are blinded to baseline and prior visit scores
- **Embedded randomized, double-blind portion of trial (Cohort 3) to evaluate dose response between high and low dose arms of SRK-015**

Six-Month Interim Analysis Results

Yung Chyung, M.D.
Chief Medical Officer



TOPAZ Interim Analysis Results Demonstrate Proof-of-Concept

Multiple lines of evidence supporting the potential clinical effect of SRK-015

	Ambulatory Patients (Revised Hammersmith Scale)			Non-Ambulatory Patients (Hammersmith Functional Motor Scale Expanded)		
	Cohort 1			Cohort 2*	Cohort 3*	
	20 mg/kg pooled (n=23)	20 mg/kg monotherapy (n=11)	20 mg/kg +nusinersen (n=12)	20 mg/kg +nusinersen (n=14)	2 mg/kg +nusinersen (n=9)	20 mg/kg +nusinersen (n=9)
Mean change from baseline (95% CI)	0.5 (-1.1, 2.2)	0.7 (-2.5, 4.0)	0.3 (-1.4, 2.0)	1.4 (0.1, 2.7)	2.4 (-0.9, 5.8)	5.6 (2.5, 8.7)
# (%) patients achieving ≥1-pt increase	12/23 (52%)	7/11 (64%)	5/12 (42%)	10/14 (71%)	6/9 (67%)	9/9 (100%)
# (%) patients achieving ≥3-pt increase	6/23 (26%)	4/11 (36%)	2/12 (17%)	3/14 (21%)	4/9 (44%)	6/9 (67%)


- ✓ **Mean improvements from baseline in HFMSE/RHS observed in each of the 3 cohorts**
 - 67% of total patients achieved ≥1-point improvement in Hammersmith scores
- ✓ **Substantial proportion of patients in each cohort attained ≥3-point improvement in HFMSE/RHS**
 - High bar and uncommon to observe in any given patient
 - 35% of total patients achieved ≥3-point improvement in Hammersmith scores
- ✓ **Dose response demonstrated in Cohort 3 (*randomized, double-blind, parallel arm design*)**
 - Greater improvements in HFMSE scores for high-dose arm across evaluated timepoints
 - Supportive PK/PD results; high dose led to higher drug exposure and target engagement

*3 patients (1 in Cohort 2 and 2 in Cohort 3) each missed 3 doses of SRK-015 and the 6-month interim analysis timepoint due to COVID-19-related site access restrictions; the six-month timepoint from these patients was not included in the interim analysis.
Data on file. Scholar Rock, Inc. Cambridge, MA


Cohort 1: Improvement in RHS Observed with Both SRK-015 Monotherapy and as Add-on to Background Nusinersen

Ambulatory Type 3 SMA	SRK-015 (20 mg/kg) pooled (n=23)	SRK-015 (20 mg/kg) monotherapy (n=11)	SRK-015 (20 mg/kg) +nusinersen (n=12)
Mean change from baseline in RHS (95% CI)	0.5 (-1.1, 2.2)	0.7 (-2.5, 4.0)	0.3 (-1.4, 2.0)
# (%) patients achieving ≥ 1 -pt increase in RHS	12/23 (52%)	7/11 (64%)	5/12 (42%)
# (%) patients achieving ≥ 3 -pt increase in RHS	6/23 (26%)	4/11 (36%)	2/12 (17%)
# (%) patients achieving ≥ 5 -pt increase in RHS	2/23 (9%)	1/11 (9%)	1/12 (8%)

Individual RHS responses




Mean (\pm SEM) change from baseline in RHS scores




Cohort 2: Meaningful and Consistent Improvements in HFMSE Observed in Type 2 and Non-Ambulatory Type 3 SMA

Type 2 and Non-Ambulatory Type 3 SMA	SRK-015 (20 mg/kg) + nusinersen (n=14)
Mean change from baseline in HFMSE (95% CI)	1.4 (0.1, 2.7)
# (%) patients achieving ≥ 1 -pt increase in HFMSE	10/14 (71%)
# (%) patients achieving ≥ 3 -pt increase in HFMSE	3/14 (21%)
# (%) patients achieving ≥ 5 -pt increase in HFMSE	2/14 (14%)

Individual HFMSE responses



Mean (\pm SEM) change from baseline in HFMSE scores




Cohort 3: SRK-015 High Dose Showed Substantially Greater Improvements in HFMSE scores Than Low Dose


Cohort 3 has a randomized, double-blind, parallel arm design embedded within TOPAZ

Type 2 SMA	SRK-015 low dose (2 mg/kg) +nusinersen (n=9)	SRK-015 high dose (20 mg/kg) +nusinersen (n=9)
Mean change from baseline in HFMSE (95% CI)	2.4 (-0.9, 5.8)	5.6 (2.5, 8.7)
# (%) patients achieving ≥ 1 -pt increase in HFMSE	6/9 (67%)	9/9 (100%)
# (%) patients achieving ≥ 3 -pt increase in HFMSE	4/9 (44%)	6/9 (67%)
# (%) patients achieving ≥ 5 -pt increase in HFMSE	3/9 (33%)	5/9 (56%)

Individual HFMSE responses




Mean (\pm SEM) change from baseline in HFMSE scores



Cohort 3: Time Course Data Supportive of Dose Response

Mean (\pm SEM) change from baseline in HFMSE scores




- High-dose arm outperformed low-dose arm numerically across the timepoints
- Plateau in improvement appears to not yet have been reached at the 6-month interim analysis timepoint
- 12-month and extension data enable evaluating the potential for durability of effect and for further motor function gains

Greater improvements in HFMSE scores observed with high dose (20 mg/kg) across all timepoints


Pharmacokinetic and Pharmacodynamic Data are Supportive of Clinically Observed Dose Response

Pharmacokinetics* (PK)



- Well-behaved PK profile consistent with that commonly observed with monoclonal antibodies
- Drug exposure was dose proportional

Pharmacodynamics (PD)



- Target engagement by SRK-015 was confirmed
- Low dose (2 mg/kg) yielded lower level of target engagement and did not achieve full target saturation

High dose (20 mg/kg) yielded higher levels of drug exposure and target engagement than low dose (2 mg/kg)

*Starting at day 28, measures are pre-dose trough levels

Data on file. Scholar Rock, Inc. Cambridge, MA

No Safety Signals Identified from Interim Analysis

Treatment-emergent adverse events (TEAEs)	SRK-015 2 mg/kg dose (n=10)	SRK-015 20 mg/kg dose (n=48)	Total (n=58)
Any TEAE	9 (90%)	40 (83.3%)	49 (84.5%)
Any Serious TEAE	0 (0.0%)	1 (2.1%)	1 (1.7%)
Any TEAE leading to study drug discontinuation	0 (0.0%)	1 (2.1%)	1 (1.7%)
Any Grade 3 (severe) or higher TEAE	0 (0.0%)	0 (0.0%)	0 (0.0%)

- **Five most frequently reported TEAEs:** Headache, upper respiratory tract infection, pyrexia, nasopharyngitis, and cough.
- **1 serious TEAE (Cohort 1):** Assessed by trial investigator as unrelated to SRK-015. Grade 2 viral upper respiratory infection (prior history) and was hospitalized. Event resolved without sequelae.
- **1 study drug discontinuation (Cohort 1):** Assessed by trial investigator as unrelated to SRK-015. Grade 2 leg muscle fatigue (developed prior to enrollment). Withdrew consent after ~2 months on trial.

Incidence and severity of AEs are consistent with underlying patient population and background therapy

TOPAZ Interim Analysis Results Demonstrate Proof-of-Concept

1. Multiple lines of evidence supporting the potential clinical effect of SRK-015

- **Dose response demonstrated in randomized, double-blind, parallel arm Cohort 3**
 - High-dose arm showed greater improvements in HFMSE scores
 - Supportive PK/PD results
- **Cohort 2 observed improvements from baseline**
 - In population for which SMN upregulator therapy alone offers motor function stabilization rather than improvement
- **Substantial % of patients in each cohort attained ≥ 3 -pt increase in Hammersmith score**
 - High bar and uncommon to observe in any given patient

2. SRK-015's broad and meaningful therapeutic potential in SMA

- **Mean improvements in Hammersmith scores observed across all 3 cohorts**
- **Most patients experienced an improvement (≥ 1 -pt increase in Hammersmith scores)**
 - Cohort 1: 52% (pooled)
 - Cohort 2: 71%
 - Cohort 3: 100% high dose, 67% low dose
- **Potential for durability and further improvements**
 - Effects observed through 6 months of treatment
 - Plateau in improvement has not yet been observed in Cohorts 2 or 3
 - 12-month and extension data enable evaluation for potential durability of effect and further improvements

Summary and Next Steps


Tony Kingsley
President & CEO



Beyond the TOPAZ Interim Analysis



- **Top-line data for 12-month treatment period expected 2Q21**
 - Longer-term evaluation of efficacy for potential durability of clinical effect and continued motor function gains
 - Longer-term safety, PK, PD, and anti-drug antibody
- **39 of 39 patients who have completed 12-month study have opted into the extension period (as of October 23, 2020)**
- **Registrational trial preparations ongoing**
- **Look forward to meeting with regulatory authorities to discuss regulatory path**




Interim results highlight SRK-015's potential as an important treatment for patients with SMA

Unlocking the Potential of the Scholar Rock R&D Engine

TGF β Superfamily: More than 30 Related Growth Factors that Mediate Diverse Biological Processes

Targeting the latent forms of growth factors



Scholar Rock seeks to unlock the therapeutic potential of modulating growth factor biology

Emerging Insights

Demonstration of proof-of-concept for SRK-015 in SMA

Validation of therapeutic potential for blocking the activation of latent myostatin with SRK-015

Validation of therapeutic potential in targeting latent forms of growth factors

Opportunities Beyond TOPAZ

- Broader exploration of SMA types, age range, and background SMN therapies
- Potential for motor function improvement in other neuromuscular disorders
- Exploration of additional indications related to broader myostatin and fast-twitch fiber biology
- Antibodies against the latent forms of additional well-validated targets in oncology (e.g. SRK-181 program) and fibrosis
- Discovery platform to generate mAbs against other latent growth factors

Differentiated Pipeline with a Series of Anticipated Milestones

